Work

A Novel Actin Binding Drug withIn VivoEfficacy

Year: 2018

Type: article

Abstract: Furthermore, a disruption of actin-mediated cellular processes, such as endocytosis, nuclear segregation, and hyphal formation, was observed. All of these processes require the formation of stable actin cables, which are disrupted following the addition of a subinhibitory concentration of occidiofungin. We were also able to demonstrate the effectiveness of occidiofungin in treating a vulvovaginal yeast infection in a murine model. The results of this study are important for the development of an efficacious novel class of actin binding drugs that may fill the existing gap in treatment options for fungal infections or different types of cancer.

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.01585-18

Authors: Akshaya Ravichandran, Mengxin Geng, Kenneth G. Hull, Jing Li, Daniel Romo, Shi-En Lu, Aaron Albee, Christopher Nutter, Donna M. Gordon, Mahmoud A. Ghannoum, Steve W. Lockless, Leif Smith

Institutions: Texas A&M University, Baylor University, Mississippi State University, University Hospitals of Cleveland, Case Western Reserve University

Language: English

Topic: Antifungal resistance and susceptibility

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: Welch Foundation, Cancer Prevention and Research Institute of Texas, Texas A and M University, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases

Awards: Lead Compound Discovery from Engineered Analogs of Occidiofungin, Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin, Examination of the Pharmacological Properties of a Novel Antifungal Named Occidiofungin, G8777267907, Mississippi INBRE

OpenAlex ID: W2896895704

FWCI: 3.209

Cites: 61

Cited by: 34

Related to: 10